Clinical Trial

Intravenous Tranexamic Acid

Study acronym: TXA
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2025 (before its estimated February 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.
Trial Details
NCT Number NCT07192640
Lead Sponsor Ain Shams University
Conditions Obese Patients, Obese Patients With Bariatric Surgery, Bleeding
Enrollment 128 participants
Start Date 2025-10-15
Primary Completion 2026-02-15 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-25